Full-Time

Medical Science Liaison

Updated on 9/3/2026

Braeburn

Braeburn

201-500 employees

Develops next-generation OUD medications with counseling

No salary listed

New Mexico, USA + 5 more

More locations: Texas, USA | Nevada, USA | Arizona, USA | Colorado, USA | Utah, USA

Remote

Residency in Utah, Colorado, Arizona, New Mexico, Texas, or Nevada required.

PharmD, PhD

Category
Medical, Clinical & Veterinary (1)

Get referred to Braeburn

See people who can refer or advise you

Requirements
  • Advanced degree in a health-sciences related field such as a PharmD, MD, DO, PhD
  • 5+ previous MSL or relevant pharmaceutical industry experience preferred
  • Candidate must hold a valid driver’s license and be able to travel up to 60–70%
  • Ability to travel up to 60–70%
  • Experience in addiction medicine preferred
Responsibilities
  • Provide disease state awareness, product information and pharmacoeconomic analyses as presentations or other forms of scientific exchange to managed care organizations, payers, and other formulary decision makers per unsolicited
  • Maintain comprehensive, up-to-date scientific expertise of disease state, clinical information, product data, and the competitor landscape within the relevant therapeutic area(s)
  • Identify and develop peer-to-peer relationships with Key Opinion Leaders (KOLs) by engaging in ongoing and balanced scientific exchanges in disease areas of strategic importance to Braeburn
  • Present scientific product-related data and disease awareness information in the hospital, institutional, and academic settings
  • Serve as liaison between healthcare professionals and Braeburn for unsolicited Investigator-Initiated Trials (IITs)
  • Address unsolicited requests for medical information from healthcare professionals via written and verbal responses, with appropriate documentation
  • Support Company sponsored trials and other research initiatives including clinical trial site recruitment as needed
  • Support external healthcare professional Speaker Training and provide Advisory Board support as needed
  • Present information for initial and ongoing training of internal and external partners pertaining to disease state, product and competitive landscape information
  • Provide medical booth and session coverage at scientific/medical meetings
  • Align day-to-day activities with Medical Affairs strategic objectives, with flexibility depending upon evolving business needs
  • Proactively and collegially interact with other field-based and internal colleagues; provide information to internal colleagues regarding regional and local issues that impact business and/or healthcare practice
  • Always comply with company and compliance policies, and internal and external guidelines
  • Support internal Medical Affairs projects as requested
Desired Qualifications
  • Understanding of the managed care arena and the application of pharmacoeconomic principles is desirable
  • Experience in addiction medicine preferred
  • 5+ previous MSL or relevant pharmaceutical industry experience preferred

Braeburn focuses on developing next-generation medications for opioid use disorder (OUD) and sells these therapies to healthcare providers, clinics, and patients with the aim of supporting recovery. The medicines are intended to be used together with counseling and support services as part of a comprehensive treatment plan for OUD. The company advances its goal through research, development, and commercialization of therapies, often in partnerships with other healthcare organizations, within the regulated pharmaceutical market. Unlike many generic care models, Braeburn emphasizes a mission-driven approach that combines medical treatments with patient support to help individuals reintegrate into their communities. The overall aim is to reduce the opioid crisis by providing effective, accessible treatments that help patients overcome addiction and rebuild their lives.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$266M

Headquarters

Washington DC, District of Columbia

Founded

2012

Get referred to Braeburn

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Camurus reported Q2 2026 Brixadi royalties up 42%, signaling accelerating U.S. uptake.
  • Braeburn presented March and June 2026 data in JAMA Internal Medicine and CPDD.
  • Brixadi penetration exceeded 30% of the long-acting buprenorphine segment by July 2026.

What critics are saying

  • Indivior's SUBLOCADE attacks Braeburn's core market, and FDA reconsideration is unresolved since May 2026.
  • BRIXADI's intravenous-abuse warning triggers REMS burden and liability exposure through 2026.
  • Camurus talks to buy Braeburn threaten standalone control and could unwind U.S. economics.

What makes Braeburn unique

  • Braeburn owns BRIXADI, the only weekly-and-monthly injectable buprenorphine, approved May 2023.
  • FDA REMS distribution and healthcare-administered dosing create sticky channel control.
  • Camurus partnership gives Braeburn FluidCrystal technology and global opioid-treatment credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-3%
New York Globe
Sep 12th, 2025
Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet

Swedish biotech Camurus in talks to buy New York Globe-based Braeburn in $1 billion opioid market bet.

Braeburn
Sep 30th, 2024
Braeburn Debuts Inspiring Docuseries Celebrating Advocates Uplifting Communities to Combat the Opioid Crisis

(PLYMOUTH MEETING, PA - September 30, 2024) - Braeburn Inc. today announced the launch of Reframe and Reclaim: Shaping the Future of Recovery Stories, a mini docuseries on BraeburnRx.com aimed at destigmatizing opioid use disorder (OUD) and celebrating the compelling advocacy of community champions.

We-Ha.com LLC
Jul 6th, 2023
New Principal Named for West Hartford's Braeburn Elementary School

She will take over for Kim Ambroise, who had served as Braeburn’s interim principal since late 2022, following the departure of the former principal, Jeff Sousa, for a superintendent position in New Hartford.

Cision
May 23rd, 2023
Camurus Announces Fda Approval Of Brixadi™ For The Treatment Of Moderate To Severe Opioid Use Disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder. .

Braeburn
Sep 24th, 2021
Braeburn hires Joshua M. Cohen as Chief Medical Officer

Braeburn announces that Joshua M. Cohen, MD, MPH, FAHS has joined the company as Chief Medical Officer.